Attached files
| file | filename |
|---|---|
| EX-32.1 - CERTIFICATION - Cure Pharmaceutical Holding Corp. | curr_ex321.htm |
| EX-31.2 - CERTIFICATION - Cure Pharmaceutical Holding Corp. | curr_ex312.htm |
| EX-31.1 - CERTIFICATION - Cure Pharmaceutical Holding Corp. | curr_ex311.htm |
| EX-23.1 - CONSENT - Cure Pharmaceutical Holding Corp. | curr_ex231.htm |
| EX-21.1 - SUBSIDIARIES - Cure Pharmaceutical Holding Corp. | curr_ex211.htm |
| 10-K - FORM 10-K - Cure Pharmaceutical Holding Corp. | curr_10k.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Cure Pharmaceutical Holding Corp. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: March 31, 2021 | By: | /s/ Michael Redard |
|
|
|
| Michael Redard |
|
|
|
| Chief Financial Officer |
|
|
|
| (Principal Financial Officer) |
|
A signed original of this written statement required by Section 906 has been provided to Cure Pharmaceutical Holding Corp. and will be retained by Cure Pharmaceutical Holding Corp. and furnished to the Securities and Exchange Commission or its staff upon request.